Ottobock account plan
Advanced prosthetics orthotics mobility
At a glance
Ottobock is a German maker of prosthetics, orthotics and exoskeletons with a patient care network; 2025 revenue was € 1,679.8 million.
Ottobock SE & Co. KGaA, based in Duderstadt, Germany, develops and makes prosthetics, neuro-orthotics, digital orthotics and prosthetics (O&P) solutions and occupational exoskeletons, and runs the Ottobock.care network of over 420 clinics and satellites in 33 countries. Its customers are O&P professionals, distributors, public institutions and amputee and neurological patients; with partners it reached patients in more than 132 countries in 2025. FY2025 revenue was € 1,679.8 million (+4.7%), core revenue € 1,599.7 million and underlying core EBITDA € 415.3 million (26.0% margin), with an average headcount of 9,275 FTE. It has been listed on the Frankfurt Stock Exchange since 9 October 2025; the Näder Family Office holds 82.44%.
Business units
EMEA
71.4% of 2025 group revenue (€ 1,199.7 million)Europe, Middle East and Africa host headquarters, the central distribution hub and most production sites, including the low-cost Bulgarian platform. Revenue grew 10.9% to € 961.4 million in January-September 2026, with B2B organic growth of 14.4% and softer Western Europe due to reimbursement processes; Russia contributed more than 11% of group revenue.
Americas
21.9% of 2025 group revenue (€ 368.2 million)North and South America, where 2025 B2B growth came from Genium X4, Kenevo reimbursement for K2 amputees in the U.S. and the C-Brace. Revenue fell 3.3% to € 257.6 million in January-September 2026, with U.S. B2B flat on customer destocking, the end of a Canadian programme and delayed tenders in Brazil.
APAC
6.7% of 2025 group revenue (€ 111.9 million)Asia Pacific, with local production in Tongzhou, China and demand for microprocessor knees. Revenue grew 5.8% to € 88.9 million in January-September 2026, accelerating in Q3 on tender catch-up in Australia and Thailand.
Products & components (B2B)
53.4% of 2025 revenue (€ 896.2 million)Prosthetics (Genium X4 and Kenevo knees, Taleo feet, the michelangelo hand), neuro-orthotics (C-Brace, Exopulse Suit), digital O&P and SuitX exoskeletons; Ottobock holds around 35% to 40% of the B2B market. Revenue grew 9.1% to € 709.3 million in January-September 2026.
Patient care (B2C)
41.9% of 2025 revenue (€ 703.4 million)The Ottobock.care clinic network fitting amputees and people with neurological mobility constraints; Ottobock is the second-largest provider in this fragmented market with approximately 5%. Revenue grew 6.9% to € 542.6 million in January-September 2026, with organic growth of 3.3%.
Strategic priorities
- Innovation and reimbursement
- Ottobock aims to advance the standard of care in prosthetics and neuro-orthotics through new products and reimbursement wins; it launched 29 new or upgraded products in 2025 and the michelangelo hand, iconiq liner and C-Brace Interim at OTWorld in 2026.
- Patient care network expansion
- Forward integration to expand, integrate and digitalise the B2C network, including the Ottobock.care brand roll-out, IT harmonisation in U.S. clinics and acquisitions such as Blatchford Norway and Rehattiva.
- Operational efficiency
- The GVEM programme, the Bulgarian shared service center and SAP S/4HANA support a margin target of 29 to 30% adjusted EBITDA in 2029.
- Digital O&P and AI
- Ottobock is building an end-to-end digital patient care chain, with AI-supported Smart Documentation launched in 2025 and AI tools now preparing reimbursement approval requests.
- Portfolio focus
- The Human Mobility wheelchair business is being sold to DH Care with closing targeted by year-end, so that from 2027 Ottobock reports only its core business.
Latest results
In January-September 2026 revenue rose 7.4% to € 1,307.9 million and core revenue 8.1% to € 1,251.8 million, with organic core growth of 6.6%. Underlying core EBITDA rose 16.4% to € 327.1 million, a 26.1% margin, and net income reached € 115.1 million. Q3 was partly below management's expectation because of a tougher reimbursement environment in Western Europe and the U.S. The 2026 guidance of 6%-8% organic core growth and an underlying core EBITDA margin above 27.0% was confirmed, though the CEO expects full-year growth between 6% and 7%.
Investments and deals
- Blatchford Norway acquisition
- On 13 May 2026 Ottobock bought 100% of Blatchford Norway AS, a Norwegian patient care brand, for € 115.3 million in cash.
- Fesia and Rehattiva acquisitions
- In July 2026 Ottobock agreed to buy Fesia Technology S.L. (Spain, functional electrical stimulation) for a preliminary € 15.0 million plus earn-out, and acquired Rehattiva Srl, an Italian patient care business.
- Neural interface ventures
- A € 4.4 million stake in Blue Arbor Technologies in February 2026, following 2025 stakes in Bionic Skins, Musclemetrix and Phantom Neuro and a € 10.0 million follow-on in ONWARD Medical.
- Capex and R&D
- CapEx was € 105.2 million in 2025 and R&D expenses € 72.7 million plus € 54.1 million capitalised; net CapEx and capitalised R&D stay at EUR 105-150 million for 2026.
- IPO
- The October 2025 IPO at € 66.00 per share placed 12,236,173 shares (€ 807.6 million).
Challenges and risks
- Tighter reimbursement
- Germany plans a reduction of approximately 3% in reimbursement rates from 2027, France cut the price of the C-Leg and Belgium cut its budget; converting a patient to revenue now takes about three months instead of one.
- U.S. approval delays and destocking
- The Genium X4 is reimbursed under a miscellaneous code, so each fitting needs separate approval, and U.S. customers adjusted inventories.
- Russia exposure
- Russia was more than 11% of group revenue in January-September 2026, bringing sanctions risk and short-seller allegations that the CFO rejects.
- Supply and cyber risks
- The largest risks in the 2025 matrix are supplier dependencies and supply shortages, IT failures from cyber-attacks and data protection penalties.
- Slower patient care growth
- B2C organic growth of 3.3% in nine months was below the company's ambition, partly due to longer approvals in Germany, France and Belgium.
What leadership says
“Our success is based on the interplay of technological excellence, integrated value creation, and immediate proximity to application”
“A 3% haircut, what we are now expecting in Germany, a year ago, was not anticipated.”
“Strategically and operationally, we are fully on track.”
“We're not expecting a margin decline”
Where a supplier can help
- Reimbursement automation
- Tied to tighter reimbursement and U.S. approval delays: documentation, payer-communication and revenue-cycle tools can shorten the approval period Ottobock is already tackling with AI.
- Clinic IT and integration
- Tied to patient care network expansion and recent acquisitions: clinic management software, IT harmonisation and integration services fit the growing Ottobock.care network.
- Finance and ERP transformation
- Tied to operational efficiency: the SAP S/4HANA implementation and the Bulgarian shared service center create needs for ERP, process and shared-services suppliers.
- Supply chain resilience
- Tied to supplier dependencies and supply shortages: second sourcing, components and supply chain visibility tools address the top-ranked risk.
- Cybersecurity and data protection
- Tied to cyber and GDPR/NIS-2 risks: security and compliance providers fit a group running clinics and connected products.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Ottobock?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report 2025
- Ottobock is a Duderstadt-based MedTech group and, by its own account, the global market leader in human bionics: prosthetics, neuro-orthotics, digital O&P and occupational exoskeletons (B2B), plus the Ottobock.care patient care network (B2C) with over 420 clinics and satellites in 33 countries.
- FY2025 revenue was € 1,679.8 million (+4.7%); core revenue € 1,599.7 million (+11.7%), with organic core growth of 10.6%, in the upper half of the 9-12% IPO guidance.
- Underlying core EBITDA rose 29.5% to € 415.3 million, a 26.0% margin (2024: 22.4%); net income € 88.3 million; free cash flow € 228.0 million; leverage down to 2.3x (2024: 3.5x).
- Products & components (B2B) € 896.2 million (+14.5%, organic 15.2%) is the growth and margin engine; patient care (B2C) € 703.4 million (+8.3%); non-core € 80.2 million after the Cascade sale and the Active Life closure.
- EMEA is 71.4% of revenue, Americas 21.9%, APAC 6.7%; growth came from Genium X4, the Taleo family, Kenevo reimbursement for K2 amputees in the U.S., C-Brace reimbursement in France and spike events.
- IPO on 9 October 2025 at € 66.00 (€ 807.6 million placed, about € 100 million primary); the Näder Family Office keeps 82.44%; included in SDAX and TecDAX; dividend proposal € 0.97 per share.
- Strategy: technology leadership and reimbursement expansion in B2B, forward integration and digitalisation of the B2C network, and the GVEM efficiency programme (shared service center and production shift to Bulgaria).
- 2026 guidance: organic core revenue growth of 5% to 8% and an underlying core EBITDA margin above 26.5%; the human mobility (wheelchair) business is being sold.
- Main risks named: supplier dependencies, IT failures and cyber-attacks, data protection penalties; also wars/conflicts and Russia sanctions, U.S. tariffs, reimbursement changes.
- Interim Financial Report H1 2026 (30 June 2026)
- H1 2026 revenue rose 6.7% to € 854.1 million; core revenue € 818.5 million (+7.7%), with organic core growth of 6.7% (H1 2025: 10.9%) and 8.0% in Q2.
- Underlying core EBITDA rose 18.1% to € 207.0 million; the margin improved to 25.3% (23.1%), and to 27.9% in Q2.
- Net income more than doubled to € 67.3 million (+140.7%); underlying net income € 85.1 million; EPS € 1.06.
- EMEA grew 11.3% (organic core 9.0%, B2B organic 14.5%); the Americas fell 6.0% with organic core growth of -0.3%; APAC -0.8% reported, organic core 3.6%.
- B2B € 461.6 million (organic 8.7%) driven by Genium X4, Kenevo and C-Brace; B2C € 356.9 million (organic 4.2%).
- Guidance specified: organic core revenue growth of 6.0-8.0% and an underlying core EBITDA margin above 27.0% (from 5-8% and above 26.5%).
- Deals: Blatchford Norway acquired in May 2026 (€ 115.3 million consideration), a € 4.4 million stake in Blue Arbor Technologies, the Human Mobility wheelchair sale signed on 19 June 2026, and Fesia Technology (Spain) signed on 7 July 2026.
- Free cash flow fell to € 71.8 million on higher tax payments; leverage 2.5x; equity ratio 17.8%.
- Quarterly Statement January - September 2026
- 9M 2026 revenue rose 7.4% to € 1,307.9 million; core revenue € 1,251.8 million (+8.1%), organic core growth 6.6% (9M 2025: 11.5%); Q3 organic core growth 6.4%.
- Underlying core EBITDA rose 16.4% to € 327.1 million; margin 26.1% (24.3%), and 27.7% in Q3.
- Net income € 115.1 million (+111.9%); underlying net income € 138.0 million; EPS € 1.79.
- EMEA organic core growth 8.7%, helped by double-digit B2B growth with Russia and Ukraine contributing; Western Europe softer as reimbursement processes lengthened. Russia contributed more than 11% of group revenue.
- Americas organic core growth -0.8% (B2B down against a strong comparison); APAC 8.6% after Q3 momentum.
- B2B € 709.3 million (organic 9.1%, michelangelo hand among drivers); B2C € 542.6 million (organic 3.3%).
- Free cash flow € 151.1 million (€ 172.8 million) on € 33.9 million higher tax payments; leverage 2.3x.
- Guidance confirmed: organic core revenue growth 6-8%, underlying core EBITDA margin above 27.0%; Rehattiva (Italy) acquired in July.
- Q3 2026 earnings call transcript
- CEO Oliver Jakobi said Q3 "was partly below our expectation due to the changed reimbursement environment"; 9M organic core growth 6.6%, Q3 6.4%.
- Guidance of 6%-8% growth and a margin above 27% confirmed, but Jakobi now expects full-year 2026 growth "between 6% and 7%".
- Reimbursement pressure in Western Europe: an approximately 3% cut in German rates from 2027, price cuts in France (C-Leg) and Belgium (budget), and longer approval times in Germany, France, Belgium and the U.S.
- Management sees a probable impact of about 1 percentage point on growth; 2027 and midterm guidance will come in March 2027.
- Russia contributed 3.5 points of EMEA's 8.7% growth; "spike events" will no longer be reported separately because the Ukraine/Russia patient base is now normal business.
- B2B grew 9.1% (Q3 9.9%) and is the growth engine; Patient Care 3.3% (Q3 1.7%) is below ambition; the Americas fell 0.8% on U.S. destocking, the end of Canada's War Amps program and delayed Brazilian tenders.
- CFO Arne Kreitz: margin drivers (mix, scale, efficiency) stay intact, "We're not expecting a margin decline"; leverage target below 2x at year-end; a 25% effective tax rate remains the guide.
- Countermeasure: AI tools and an ambient listening tool to prepare reimbursement approval requests and shorten approval times next year.
- H1 2026 earnings call transcript
- CEO Oliver Jakobi: "Strategically and operationally, we are fully on track"; H1 organic core growth 6.7%, Q2 8%, with Q1 timing effects normalised.
- Guidance narrowed: growth range lifted at the low end from 5% to 6% (top stays 8%); margin guidance raised to above 27% from above 26.5%.
- Underlying EBITDA margin 25.3% in H1 and 27.9% in Q2; CFO Arne Kreitz targets roughly 1 point of margin gain per year in the midterm and leverage below 2x by year-end.
- B2B grew 8.7% in H1 and 11.7% in Q2, broad-based across high-end mechatronics, feet, liners, new mechanical knees and the Michelangelo Hand.
- U.S. B2B grew 1% in H1, with what the CFO called a catch-up to 4% in Q2; Canada (War Amps program on hold) and Brazil (no tenders before elections) weighed on the Americas.
- M&A: Blatchford's patient care business in Norway (market leader, margin similar to B2B) and Fesia (functional electrical stimulation); expected to beat the 8.5-9% WACC.
- Human Mobility wheelchair business sold to DHCare, closing expected at year-end; from next year only the core business will be reported.
- Spike events add 1-2 points of EMEA's 9% growth; Ukraine has about 150,000 new amputees since the war began versus 8,000-10,000 fittings a year before.
- Ottobock-CFO zieht positives Fazit nach einem Jahr Börsennotierung (Börsen-Zeitung interview)
- CFO Arne Kreitz, a year after the October 2025 IPO, says (translated) "We have delivered what we promised", with the share about 15% below the € 66 issue price, which he puts down to sector-wide derating and capital flowing to tech and energy.
- The IPO brought financial and strategic flexibility (e.g. human-machine interfaces), capital market discipline and visibility, including with job applicants; only about € 100 million of the € 808 million proceeds went to Ottobock.
- 2026 deals: Blatchford's Norwegian patient care business for € 110 million, Fesia Technology (functional electrical stimulation) and a $5 million stake in Blue Arbor Technologies.
- Midterm targets: organic growth of 7-9% a year to 2029 and an adjusted EBITDA margin of 29-30% in 2029, from scale, mix and efficiency (over 600 staff in Bulgaria).
- Ottobock is about twice the size of the next player in products and components; the U.S. remains the key Americas market; Canada and Brazil were H1 one-offs.
- Leverage near 2x at year-end; an € 850 million syndicated loan to 2029 with an accordion; no bond or rating needed; dividend 30-40% of adjusted net income, but growth has priority.
- The Human Mobility sale to DH Care removes € 64 million of 2025 revenue with very low EBITDA; Orthopedic Services (about € 10 million revenue, U.S.) remains non-core.
- Russia was 8.8% of revenue at the IPO and slightly above 10% in H1 2026; Kreitz rejects Grizzly Research's claims and says Ottobock filed a market manipulation complaint with BaFin.
Questions about Ottobock
What does Ottobock do?
Ottobock develops and makes prosthetics, neuro-orthotics, digital O&P solutions and exoskeletons, and fits patients through its Ottobock.care network of over 420 clinics and satellites in 33 countries.
What is Ottobock's revenue?
FY2025 revenue was € 1,679.8 million (+4.7%). In January-September 2026 revenue was € 1,307.9 million (+7.4%).
How many employees does Ottobock have?
Average headcount was 9,275 FTE in 2025 and average FTE was 9,455 in January-September 2026.
Who leads Ottobock?
Oliver Jakobi is CEO and Chief Sales Officer, Dr. Arne Kreitz is CFO, and Prof. Hans Georg Näder chairs the Management Board of the general partner.
What is Ottobock's strategy?
Three pillars: innovation and technology leadership scaled through B2B, forward integration of the patient care network, and operational excellence, with a target of 29 to 30% adjusted EBITDA margin in 2029.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)